191 related articles for article (PubMed ID: 37358557)
1. Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia Cells.
Sullivan-Reed K; Toma MM; Drzewiecka M; Nieborowska-Skorska M; Nejati R; Karami A; Wasik MA; Sliwinski T; Skorski T
Mol Cancer Res; 2023 Oct; 21(10):1017-1022. PubMed ID: 37358557
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
Sullivan-Reed K; Bolton-Gillespie E; Dasgupta Y; Langer S; Siciliano M; Nieborowska-Skorska M; Hanamshet K; Belyaeva EA; Bernhardy AJ; Lee J; Moore M; Zhao H; Valent P; Matlawska-Wasowska K; Müschen M; Bhatia S; Bhatia R; Johnson N; Wasik MA; Mazin AV; Skorski T
Cell Rep; 2018 Jun; 23(11):3127-3136. PubMed ID: 29898385
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of synthetic lethality between BRCA1/2 and 53BP1 deficiencies and DNA polymerase theta targeting.
Ronson GE; Starowicz K; Anthony EJ; Piberger AL; Clarke LC; Garvin AJ; Beggs AD; Whalley CM; Edmonds MJ; Beesley JFJ; Morris JR
Nat Commun; 2023 Nov; 14(1):7834. PubMed ID: 38030626
[TBL] [Abstract][Full Text] [Related]
4. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
Cramer-Morales K; Nieborowska-Skorska M; Scheibner K; Padget M; Irvine DA; Sliwinski T; Haas K; Lee J; Geng H; Roy D; Slupianek A; Rassool FV; Wasik MA; Childers W; Copland M; Müschen M; Civin CI; Skorski T
Blood; 2013 Aug; 122(7):1293-304. PubMed ID: 23836560
[TBL] [Abstract][Full Text] [Related]
5. POLθ-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosis.
Llorens-Agost M; Ensminger M; Le HP; Gawai A; Liu J; Cruz-García A; Bhetawal S; Wood RD; Heyer WD; Löbrich M
Nat Cell Biol; 2021 Oct; 23(10):1095-1104. PubMed ID: 34616022
[TBL] [Abstract][Full Text] [Related]
6. Distinct roles of RAD52 and POLQ in chromosomal break repair and replication stress response.
Kelso AA; Lopezcolorado FW; Bhargava R; Stark JM
PLoS Genet; 2019 Aug; 15(8):e1008319. PubMed ID: 31381562
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors.
Fried W; Tyagi M; Minakhin L; Chandramouly G; Tredinnick T; Ramanjulu M; Auerbacher W; Calbert M; Rusanov T; Hoang T; Borisonnik N; Betsch R; Krais JJ; Wang Y; Vekariya UM; Gordon J; Morton G; Kent T; Skorski T; Johnson N; Childers W; Chen XS; Pomerantz RT
Nat Commun; 2024 Apr; 15(1):2862. PubMed ID: 38580648
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Lethality Targeting Polθ.
Drzewiecka M; Barszczewska-Pietraszek G; Czarny P; Skorski T; Śliwiński T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741863
[TBL] [Abstract][Full Text] [Related]
9. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ
Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467
[TBL] [Abstract][Full Text] [Related]
10. The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
Hromas R; Kim HS; Sidhu G; Williamson E; Jaiswal A; Totterdale TA; Nole J; Lee SH; Nickoloff JA; Kong KY
Breast Cancer Res; 2017 Nov; 19(1):122. PubMed ID: 29145865
[TBL] [Abstract][Full Text] [Related]
11. Genetic separation of Brca1 functions reveal mutation-dependent Polθ vulnerabilities.
Krais JJ; Glass DJ; Chudoba I; Wang Y; Feng W; Simpson D; Patel P; Liu Z; Neumann-Domer R; Betsch RG; Bernhardy AJ; Bradbury AM; Conger J; Yueh WT; Nacson J; Pomerantz RT; Gupta GP; Testa JR; Johnson N
Nat Commun; 2023 Nov; 14(1):7714. PubMed ID: 38001070
[TBL] [Abstract][Full Text] [Related]
12. Polθ is phosphorylated by PLK1 to repair double-strand breaks in mitosis.
Gelot C; Kovacs MT; Miron S; Mylne E; Haan A; Boeffard-Dosierre L; Ghouil R; Popova T; Dingli F; Loew D; Guirouilh-Barbat J; Del Nery E; Zinn-Justin S; Ceccaldi R
Nature; 2023 Sep; 621(7978):415-422. PubMed ID: 37674080
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP) ribose polymerase promotes DNA polymerase theta-mediated end joining by activation of end resection.
Luedeman ME; Stroik S; Feng W; Luthman AJ; Gupta GP; Ramsden DA
Nat Commun; 2022 Aug; 13(1):4547. PubMed ID: 35927262
[TBL] [Abstract][Full Text] [Related]
14. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours.
Barszczewska-Pietraszek G; Drzewiecka M; Czarny P; Skorski T; Śliwiński T
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613762
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
[TBL] [Abstract][Full Text] [Related]
16. DNA polymerase θ protects leukemia cells from metabolically induced DNA damage.
Vekariya U; Toma M; Nieborowska-Skorska M; Le BV; Caron MC; Kukuyan AM; Sullivan-Reed K; Podszywalow-Bartnicka P; Chitrala KN; Atkins J; Drzewiecka M; Feng W; Chan J; Chatla S; Golovine K; Jelinek J; Sliwinski T; Ghosh J; Matlawska-Wasowska K; Chandramouly G; Nejati R; Wasik M; Sykes SM; Piwocka K; Hadzijusufovic E; Valent P; Pomerantz RT; Morton G; Childers W; Zhao H; Paietta EM; Levine RL; Tallman MS; Fernandez HF; Litzow MR; Gupta GP; Masson JY; Skorski T
Blood; 2023 May; 141(19):2372-2389. PubMed ID: 36580665
[TBL] [Abstract][Full Text] [Related]
17. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
18. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
Ceccaldi R; Liu JC; Amunugama R; Hajdu I; Primack B; Petalcorin MI; O'Connor KW; Konstantinopoulos PA; Elledge SJ; Boulton SJ; Yusufzai T; D'Andrea AD
Nature; 2015 Feb; 518(7538):258-62. PubMed ID: 25642963
[TBL] [Abstract][Full Text] [Related]
19. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
20. IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.
Maifrede S; Martin K; Podszywalow-Bartnicka P; Sullivan-Reed K; Langer SK; Nejati R; Dasgupta Y; Hulse M; Gritsyuk D; Nieborowska-Skorska M; Lupey-Green LN; Zhao H; Piwocka K; Wasik MA; Tempera I; Skorski T
Mol Cancer Res; 2017 Aug; 15(8):967-972. PubMed ID: 28634224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]